公开(公告)号：US10849902B2

公开(公告)日：2020-12-01

申请号：US16065362

申请日：2016-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahisa Matsuda ,  Takashi Motoyaji ,  Shuji Kitamura ,  Masato Yoshida

IPC: A61K31/517 ,  A61K31/519 ,  A61P9/04

Abstract: The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

公开(公告)号：US10786506B2

公开(公告)日：2020-09-29

申请号：US16065362

申请日：2016-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahisa Matsuda ,  Takashi Motoyaji ,  Shuji Kitamura ,  Masato Yoshida

IPC: A61K31/517 ,  A61K31/519 ,  A61P9/04

Abstract: The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

公开(公告)号：US20200054637A1

公开(公告)日：2020-02-20

申请号：US16065362

申请日：2016-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahisa Matsuda ,  Takashi Motoyaji ,  Shuji Kitamura ,  Masato Yoshida

IPC: A61K31/519 ,  A61P9/04

Abstract: The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

公开(公告)号：US12202832B2

公开(公告)日：2025-01-21

申请号：US16608723

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji Kitamura ,  Zenichi Ikeda ,  Minoru Ikoma ,  Koji Watanabe ,  Hideki Hirose ,  Takafumi Yukawa ,  Sachie Morimoto ,  Naoki Nishizawa ,  Taiji Asami

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4184 ,  A61K47/38 ,  A61P9/04

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

公开(公告)号：US12162864B2

公开(公告)日：2024-12-10

申请号：US17280628

申请日：2019-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinobu Sasaki ,  Yasutomi Asano ,  Hironobu Maezaki ,  Ayumu Sato ,  Kazuaki Takami ,  Masaki Seto ,  Haruhi Ando ,  Shuji Kitamura ,  Steve L. Swann

IPC: C07D405/14 ,  A61K9/00 ,  A61K9/20 ,  A61P1/10 ,  C07D309/14 ,  C07D407/12 ,  C07D407/14

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10919891B2

公开(公告)日：2021-02-16

申请号：US16608140

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji Kitamura ,  Zenichi Ikeda ,  Sachie Morimoto ,  Minoru Ikoma ,  Koji Watanabe ,  Hideki Hirose ,  Takafumi Yukawa ,  Kenjiro Sato

IPC: C07D471/04 ,  A61P9/06 ,  A61P9/12

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

公开(公告)号：US10519110B2

公开(公告)日：2019-12-31

申请号：US16175144

申请日：2018-10-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasutomi Asano ,  Takuto Kojima ,  Osamu Kurasawa ,  Tzu-Tshin Wong ,  Yasuhiro Hirata ,  Naoki Iwamura ,  Bunnai Saito ,  Yuta Tanaka ,  Ryosuke Arai ,  Shinichi Imamura ,  Kazuko Yonemori ,  Yasufumi Miyamoto ,  Shuji Kitamura ,  Osamu Sano

IPC: C07D211/58 ,  C07F9/6509 ,  C07D401/14 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/661 ,  A61K33/22 ,  C07D215/42 ,  C07D401/06 ,  C07D401/12 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07F5/02 ,  A61P3/00 ,  A61P35/00 ,  C07B59/00 ,  C07D405/06 ,  C07D413/14

Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

公开(公告)号：US10189785B2

公开(公告)日：2019-01-29

申请号：US15565891

申请日：2016-04-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasutomi Asano ,  Takuto Kojima ,  Osamu Kurasawa ,  Tzu-Tshin Wong ,  Yasuhiro Hirata ,  Naoki Iwamura ,  Bunnai Saito ,  Yuta Tanaka ,  Ryosuke Arai ,  Shinichi Imamura ,  Kazuko Yonemori ,  Yasufumi Miyamoto ,  Shuji Kitamura ,  Osamu Sano

IPC: C07D211/58 ,  C07D215/42 ,  C07D401/02 ,  C07D413/06 ,  C07D413/14 ,  A61K31/444 ,  A61K31/4709 ,  C07F9/6509 ,  C07D401/14 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/452 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/661 ,  A61K33/22 ,  C07D401/06 ,  C07D401/12 ,  C07D409/12 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07F5/02 ,  A61P3/00 ,  A61P35/00 ,  C07B59/00 ,  C07D405/06

Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

公开(公告)号：US20150018547A1

公开(公告)日：2015-01-15

申请号：US14380215

申请日：2013-02-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Nobuyuki Takakura ,  Yoshihiro Banno ,  Yoshito Terao ,  Atsuko Ochida ,  Sachie Morimoto ,  Shuji Kitamura ,  Yoshihide Tomata ,  Tsuneo Yasuma ,  Minoru Ikoma ,  Kei Masuda

IPC: C07D333/60 ,  C07D307/80 ,  C07D495/04 ,  C07D417/12 ,  C07D333/70 ,  C07D333/64 ,  C07D409/12 ,  C07D405/12

CPC classification number: C07D333/60 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81 ,  C07D307/84 ,  C07D333/54 ,  C07D333/64 ,  C07D333/70 ,  C07D405/04 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D417/12 ,  C07D495/04

Abstract: The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有GOAT抑制作用的化合物，其可用于预防或治疗肥胖症等，并且具有优异的疗效。 本发明是由式（I）表示的化合物：其中各符号如说明书中所定义，或其盐。